Advanced Breast Cancer Clinical Trials

69 recruiting

Advanced Breast Cancer Trials at a Glance

93 actively recruiting trials for advanced breast cancer are listed on ClinicalTrialsFinder across 6 cities in 51 countries. The largest study group is Phase 2 with 42 trials, with the heaviest enrollment activity in Shanghai, Houston, and Boston. Lead sponsors running advanced breast cancer studies include Fudan University, Henan Cancer Hospital, and Wenjin Yin.

Browse advanced breast cancer trials by phase

Treatments under study

About Advanced Breast Cancer Clinical Trials

Looking for clinical trials for Advanced Breast Cancer? There are currently 69 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 93 trials

Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 1

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Advanced Solid TumorAdvanced Breast CancerAdvanced Ovarian Cancer
Bristol-Myers Squibb234 enrolled21 locationsNCT06997029
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Advanced Breast CancerMetastatic Breast Cancer (HR+/ HER2-)
Pfizer260 enrolled9 locationsNCT07318805
Recruiting

A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Metastatic Breast CancerLocally Advanced Breast Cancer
Hoffmann-La Roche500 enrolled17 locationsNCT07347600
Recruiting
Phase 1Phase 2

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled39 locationsNCT06827236
Recruiting
Phase 2

A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer

Advanced Breast Cancer
Henan Cancer Hospital92 enrolled1 locationNCT07540533
Recruiting
Phase 3

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Breast CancerMetastatic Breast CancerER Positive Breast Cancer+1 more
Olema Pharmaceuticals, Inc.1,000 enrolled85 locationsNCT07085767
Recruiting
Phase 3

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Advanced Breast Cancer
AstraZeneca500 enrolled298 locationsNCT06380751
Recruiting
Phase 1

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Metastatic Breast CancerAdvanced Solid TumorAdvanced Breast Cancer
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 1

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Advanced Breast Cancer
Stemline Therapeutics, Inc.240 enrolled32 locationsNCT06638307
Recruiting
Phase 1

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

Breast CancerMetastatic Breast CancerAdvanced Breast Cancer
Boundless Bio, Inc.96 enrolled8 locationsNCT07408089
Recruiting
Phase 1Phase 2

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca564 enrolled14 locationsNCT06188520
Recruiting
Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+6 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 3

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Metastatic Breast CancerAdvanced Breast Cancer
Fudan University160 enrolled1 locationNCT06649331
Recruiting
Phase 2

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

Advanced Breast CancerAdvanced Breast Carcinoma
MedSIR200 enrolled56 locationsNCT06486883
Recruiting
Phase 2

Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
National Cancer Centre, Singapore40 enrolled1 locationNCT05286437
Recruiting
Phase 3

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Advanced Breast Cancer
MedSIR240 enrolled99 locationsNCT06382948
Recruiting
Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 1Phase 2

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Advanced Breast CancerAdvanced Solid Tumors
Ensem Therapeutics233 enrolled10 locationsNCT06993844